Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7914| Seroprevalence of hepatitis B and C viruses in moderate and severe COVID-19 inpatients: A cross-sectional study at a referral center in Mexico | |
| JUAN CARLOS RIVERA LÓPEZ MARIA FERNANDA GONZALEZ LARA GRACIELA ELIA CASTRO NARRO LUIS FEDERICO USCANGA DOMINGUEZ CARLOS MOCTEZUMA VELAZQUEZ | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| https://doi.org/10.1016/j.aohep.2022.100684 | |
| Introduction and Objectives The emergence of SARS-CoV-2, which causes the coronavirus disease (COVID-19) has caused a great impact on healthcare systems worldwide, including hepatitis B and C viruses screening and elimination programs. The high number of COVID-19 hospitalizations represent a great opportunity to screen patients for hepatitis B virus (HBV) and hepatitis C virus (HCV), which was the aim of this study. Material and Methods Cross-sectional, retrospective study performed between April 2020 and 20201 at a referral center in Mexico dedicated to the care of adults with severe/critical COVID-19. We retrieved clinical, demographic, and laboratory results from each patient´s medical records, including antibodies against HCV (anti-HCV), HBV surface antigen (HBsAg), antibodies against the HBV core antigen (anti-HBcAg), and antibodies against HBsAg (anti-HBsAg). Results Out of 3620 patients that were admitted to the hospital, 24 (0.66%), 4 (0.11%), and 72 (1.99%) tested positive for anti-HCV, HBsAg, and anti-HBcAg, respectively. Of all seronegative patients, 954 (27%) had undetectable anti-HBsAg and 401 (12%) had anti-HBsAg at protective levels. Blood transfusion was the most relevant risk factor. Only 9.7% of the anti-HBc positive, 25% of the HBsAg positive, and 52% of the anti-HCV positive were aware of their serological status. Conclusions In this study we found a prevalence of anti-HCV of 0.66%, HBsAg in 0.11%, and isolated anti-HBcAg in 1.99%. We also found that HBV vaccination coverage has been suboptimal and needs to be reinforced. This study gave us a trustworthy insight of the actual seroprevalence in Mexico, which can help provide feedback to the Hepatitis National Elimination Plan. | |
| https://www.sciencedirect.com/ | |
| 12-02-2022 | |
| Artículo | |
| https://www.sciencedirect.com/ | |
| Inglés | |
| JC Jiménez-Mendoza, FE Rivera-López, MF González-Lara, RD Valdez-Echeverría, GE Castro-Narro, A Tore, LF Uscanga-Domínguez, C Moctezuma-Velázquez, Seroprevalence of hepatitis B and C viruses in moderate and severe COVID-19 inpatients: A cross-sectional study at a referral center in Mexico, Annals of Hepatology, Volume 27, Issue 3, 2022, 100684, ISSN 1665-2681, https://doi.org/10.1016/j.aohep.2022.100684. (https://www.sciencedirect.com/science/article/pii/S1665268122000266) | |
| VIRUS RESPIRATORIOS | |
| Versión publicada | |
| publishedVersion - Versión publicada | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| Seroprevalence of hepatitis B and C viruses in moderate and severe COVID-19 inpatients A cross-sectional study at a referral center in Mexico.pdf | 303.33 kB | Adobe PDF | Visualizar/Abrir |